Emcure Pharma shares advance 10% as Kotak Equities sees 28% upside in stock

Driven by strong organic growth, an in-licensing agreement with Sanofi, the consolidation of Mantra, and the resolution of most legal challenges, Emcure is projected to achieve a 13% overall sales CAGR between FY2024 and FY2027. Enhanced productivity following a 20%+ expansion in field force since FY2022, along with increased utilisation of new facilities, is expected to contribute to robust EBITDA and EPS CAGRs of 18% and 29%, respectively, during the same period.

More To Explore

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information.

The information on this website does not constitute investment advice or a recommendation or a solicitation to engage in any investment activity. This website and its content are not intended for residents of the UAE, US, Canada, Australia, UK, Russia, North Korea, China, Japan, Hong Kong, Singapore and Iran.

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003